Tazarotene (also a third-generation selective RAR-β/RAR-γ agonist; available as Tazorac®/Fabior® 0.1% cream, gel, or foam) has additionally shown activity against BCC [305,306]; however, a clinical trial investigating its activity in patients with BCC nevus syndrome has disputed potency for this indication [307]. Here, RARG is linked to skin basal cell carcinoma.